SciBX,
Targets & Mechanisms
TAU's cease and de-cis-t letter
By Lauren Martz, Staff Writer
Published on
Thursday, April 26, 2012
Researchers at Harvard Medical School have developed isoform-specific antibodies to target phosphorylated TAU in Alzheimer's disease. The antibodies will need to be validated for early detection, treatment and prevention of the disease in patients.
To read this article, you must be a SciBX subscriber through BioCentury.
If you have subscribed to SciBX through our partner, Nature Publishing Group, please
go to
http://www.nature.com/scibx. Otherwise, please click below to contact us
or start a free trial.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
SciBX: Science-Business eXchange
BioCentury's weekly translational science journal, published in collaboration with Nature Publishing Group:
Selects from hundreds of scientific papers published each week to identify early opportunities for investment, alliances and partnerships
Reports on the most commercially relevant developments
Subscribe Now
Get Free Trial
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]